UCB

UCB.BR Large Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

€264.50

-1.23% today

52W: €129.35 – €289.50

52W Low: €129.35 Position: 84.4% 52W High: €289.50

🔗 Compare Brokers

Key Metrics

P/E Ratio

32.9x

Price-to-Earnings

Forward P/E

19.48x

Forward Price/Earnings

P/S Ratio

6.5x

Price-to-Sales

EV/EBITDA

19.22x

Enterprise Value/EBITDA

Div. Yield

55%

Annual dividend yield

Market Cap

$50.4B

Market Capitalization

Revenue Growth

26.6%

YoY Revenue Growth

Profit Margin

20.13%

Net profit margin

ROE

14.91%

Return on Equity

Beta

0.23

Market sensitivity

Short Interest

—

% of float sold short

Avg. Volume

230,108

Average daily volume

Valuation Analysis

Signal

Overvalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

20 analysts

Avg. Price Target

€284.65

+7.62% upside

Target Range

€195.00 – €340.00

About the Company

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and a

Sector: Healthcare Industry: Biotechnology Country: Belgium Employees: 9,765 Exchange: BRU